Project description DEENESFRITPL Sensor technology for detection and monitoring of upper gastrointestinal bleeding Upper gastrointestinal bleeding (UGIB) is a life-threatening emergency resulting in 2 million hospitalisations each year in Europe and the United States. The Irish company EnteraSense is developing an innovative sensor technology to detect and monitor UGIB. A capsule containing the sensor is ingested in the same way as existing capsules in the market today. The optical-based sensor acquires data from the environment during its transit along the gastrointestinal tract. The data are processed to determine the presence of blood and to send a signal to an external monitor. This technology will significantly enhance the diagnostic capabilities of gastrointestinal physicians. The current EU-funded PillSense project aims to optimise the product design, develop a commercial manufacturing process, and gain clinical approval through two stages of in-human clinical trials. Show the project objective Hide the project objective Objective Upper gastrointestinal bleeding (UGIB) is a potentially life-threatening condition that affects approx. 2 million people annually in Europe and in the United States. Current UGIB diagnosis comprises a long and slow set of laboratory tests and culminates ultimately with an endoscopy which is the only conclusive mean for UGIB diagnosis. This results in an over usage of endoscopic resources every time there is a suspicion of a bleed. Clinical data shows that up to 60% of the time endoscopy and consequent hospital admission is not necessary. In addition, endoscopy is invasive, expensive (approx. €2433) and cannot deliver prolonged monitoring. Multi-disciplinary consortium led by EnteraSense are developing a disruptive technology ‘PillSense’ which enables real-time detection of UGIB and subsequent monitoring of high risk patients without the need of endoscopy. The product includes an ingestible capsule and an external receiver. The capsule contains an optical based sensor to detect bleeding in the upper gastrointestinal tract. EnteraSense development team has already proven the core technology through lab-testing and in-vivo clinical studies. During this FTI project, the consortium aims to optimise PillSense product design, gain regulatory approvals, develop a commercial scale manufacturing process and gain clinical approval through two stages in-human clinical trials. Successful development and commercialisation will enable consortium to generate revenues of €59million and a gross profit of €29million over five years- post commercialisation. Fields of science engineering and technologymechanical engineeringmanufacturing engineeringengineering and technologyelectrical engineering, electronic engineering, information engineeringelectronic engineeringsensors Programme(s) H2020-EC - Horizon 2020 Framework Programme Main Programme H2020-EU.3. - PRIORITY 'Societal challenges H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies Topic(s) EIC-FTI-2018-2020 - Fast Track to Innovation (FTI) Call for proposal H2020-EIC-FTI-2018-2020 See other projects for this call Funding Scheme IA - Innovation action Coordinator ENTERASENSE LIMITED Net EU contribution € 1 366 734,75 Address PENN ENGINEERING MERVUE BUSINESS AND TECHNOLOGY PA H91D3T0 Galway Ireland See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Ireland Northern and Western West Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 1 952 478,21 Participants (5) Sort alphabetically Sort by Net EU contribution Expand all Collapse all ANECTO LIMITED Participation ended Ireland Net EU contribution € 0,00 Address PENN ENGINEERING, MERVUE BUSINESS & TECHNOLOGY PAR H91D3T0 GALWAY See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Ireland Northern and Western West Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost No data STERIPACK MEDICAL POLAND SP ZOO Poland Net EU contribution € 554 400,00 Address UL. JAPONSKA 1 LEG 55 220 Jelcz Laskowice See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Makroregion południowo-zachodni Dolnośląskie Wrocławski Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 792 000,00 FAKULTNI NEMOCNICE OSTRAVA Participation ended Czechia Net EU contribution € 0,00 Address 17 LISTOPADU 1790 708 52 Ostrava Poruba See on map Region Česko Moravskoslezsko Moravskoslezský kraj Activity type Research Organisations Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost No data PHARMNET S.R.O. Czechia Net EU contribution € 295 596,50 Address HRNCIRUM 20 14900 PRAHA See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Česko Praha Hlavní město Praha Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 422 280,71 SYNERGY HEALTH IRELAND LIMITED Ireland Net EU contribution € 459 025,00 Address IDA BUSINESS & TECHNOLOGY PARK DUBLIN See on map Region Ireland Eastern and Midland Dublin Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 655 750,00
